Several rapalog mTOR inhibitors, including rapamycin [4, 5], temsirolimus (CCI-779) [6–9], and everolimus (RAD001) [10], have shown preclinical potential in hematological malignancies. The gene discussed is MTOR; the disease is hematologic disorder.